176 related articles for article (PubMed ID: 23554846)
1. The role of naftopidil in the management of benign prostatic hyperplasia.
Hara N; Mizusawa T; Obara K; Takahashi K
Ther Adv Urol; 2013 Apr; 5(2):111-9. PubMed ID: 23554846
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
3. Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia.
Masumori N
Ther Clin Risk Manag; 2011; 7():227-38. PubMed ID: 21753885
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia.
Griwan MS; Karthikeyan YR; Kumar M; Singh BJ; Singh SK
Urol Ann; 2014 Jul; 6(3):181-6. PubMed ID: 25125888
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Naftopidil 75 mg with Tamsulosin Hydrochloride 0.2 mg in the Treatment of Lower Urinary Tract Symptoms with Benign Prostatic Hyperplasia.
Shigemura K; Yamamichi F; Matsumoto M; Tanaka K; Yamashita M; Arakawa S; Fujisawa M
Low Urin Tract Symptoms; 2012 Sep; 4(3):136-9. PubMed ID: 26676620
[TBL] [Abstract][Full Text] [Related]
6. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
Garimella PS; Fink HA; Macdonald R; Wilt TJ
Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
[TBL] [Abstract][Full Text] [Related]
7. Add-on Therapy With the α-Blockers Tamsulosin and Naftopidil Improves Voiding Function by Enhancing Neuronal Activity in Prostatic Hyperplasia Rats.
Ko IG; Hwang L; Jin JJ; Kim SH; Han JH; Jeon JW; Cho ST
Int Neurourol J; 2018 Mar; 22(1):20-29. PubMed ID: 29609419
[TBL] [Abstract][Full Text] [Related]
8. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
Gotoh M; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Origasa H;
BJU Int; 2005 Sep; 96(4):581-6. PubMed ID: 16104914
[TBL] [Abstract][Full Text] [Related]
9. The use of alpha1-adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia.
Nickel JC
Urology; 2003 Sep; 62(3 Suppl 1):34-41. PubMed ID: 12957198
[TBL] [Abstract][Full Text] [Related]
10. Outcomes and complications of naftopidil versus tamsulosin for elderly men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review and meta-analysis.
Chai Y; Zhou Z; Cui Y; Che X; Zhang Y
Andrologia; 2021 Oct; 53(9):e14166. PubMed ID: 34189764
[TBL] [Abstract][Full Text] [Related]
11. Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia.
Kojima Y; Sasaki S; Kubota Y; Hayase M; Hayashi Y; Shinoura H; Tsujimoto G; Kohri K
J Urol; 2008 Mar; 179(3):1040-6. PubMed ID: 18206918
[TBL] [Abstract][Full Text] [Related]
12. Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study.
Komiya A; Suzuki H; Awa Y; Egoshi K; Onishi T; Nakatsu H; Ohki T; Mikami K; Sato N; Araki K; Ota S; Naya Y; Ichikawa T
Int J Urol; 2010 Jun; 17(6):555-62. PubMed ID: 20370847
[TBL] [Abstract][Full Text] [Related]
13. Early Efficacy of an α1 Adrenoceptor Antagonist, Naftopidil, against Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia.
Ishizuka O; Nishizawa O; Takeda M; Nomura T; Kagawa S
Low Urin Tract Symptoms; 2011 Sep; 3(2):79-85. PubMed ID: 26676391
[TBL] [Abstract][Full Text] [Related]
14. History and nomenclature of alpha1-adrenoceptors.
Langer SZ
Eur Urol; 1999; 36 Suppl 1():2-6. PubMed ID: 10438241
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia].
Ikegaki I
Nihon Yakurigaku Zasshi; 2000 Aug; 116(2):63-9. PubMed ID: 10976457
[TBL] [Abstract][Full Text] [Related]
16. Naftopidil for the treatment of benign prostate hyperplasia: a systematic review.
Castiglione F; Benigni F; Briganti A; Salonia A; Villa L; Nini A; Di Trapani E; Capitanio U; Hedlund P; Montorsi F
Curr Med Res Opin; 2014 Apr; 30(4):719-32. PubMed ID: 24188134
[TBL] [Abstract][Full Text] [Related]
17. History and nomenclature of alpha1-adrenoceptors.
Langer SZ
Eur Urol; 1999; 36 Suppl 1():2-6. PubMed ID: 10393465
[TBL] [Abstract][Full Text] [Related]
18. Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia.
Momose H; Hosokawa Y; Kishino T; Ono T; Oyama N
Drugs Today (Barc); 2007 Feb; 43 Suppl A():1-10. PubMed ID: 17401467
[TBL] [Abstract][Full Text] [Related]
19. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors.
Takei R; Ikegaki I; Shibata K; Tsujimoto G; Asano T
Jpn J Pharmacol; 1999 Apr; 79(4):447-54. PubMed ID: 10361884
[TBL] [Abstract][Full Text] [Related]
20. Does prostate volume affect the efficacy of α1D/A: Adrenoceptor antagonist naftopidil?
Tanuma Y; Tanaka Y; Takeyama K; Okamoto T
Urol Ann; 2016; 8(1):20-5. PubMed ID: 26834396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
